The data from the final phase III of a dengue fever vaccine developed by Sanofi Pasteur was released on Monday.
The study, which took place in Latin America and lasted 25 months, confirmed the vaccine’s high effectiveness in protecting against severe dengue and hospitalization. With these results, the vaccine could potentially satisfy the medical needs of patients in tropical and sub-tropical areas around the globe.
Another phase III study in Asia had similar positive results, confirming the global effectiveness of the dengue fever vaccine.
Both of the studies included 31,000 candidates from 10 endemic countries.
The vaccine’s overall effectiveness in youths ages 9-16 was 60.8 percent with just three doses of the vaccine. Final analyses confirmed a 95.5 percent protection against the fever. The data also illustrated an 80.3 percent drop in hospitalization.
More than 2.5 billion people live at risk of contracting dengue fever. Experts estimate that 500,000 children and adults are hospitalized for severe dengue fever each year. This adds unnecessary strain to health care systems and health care professionals. The number of dengue fever cases has been rising due to increased travel and urbanization.
As of 2015, Sanofi Pasteur plans to apply for registration in endemic nations. Once approved, this will be the world’s first dengue fever vaccine and may be key in the World Health Organization’s goal to reduce dengue death rates by 50 percent in 2020.